Skip to main content
Clinical Trials/NCT03710551
NCT03710551
Completed
Not Applicable

Stool Composition and GI Tolerance in Infants Fed a Term Infant Formula With a New Fat Blend Plus L.Reuteri: a Randomized Controlled Trial

Société des Produits Nestlé (SPN)1 site in 1 country140 target enrollmentStarted: September 26, 2018Last updated:

Overview

Phase
Not Applicable
Status
Completed
Sponsor
Société des Produits Nestlé (SPN)
Enrollment
140
Locations
1
Primary Endpoint
Stool Consistency Score

Overview

Brief Summary

The purpose of this study is to evaluate the stool composition and GI tolerance of an experimental formula with a new fat blend plus L. reuteri vs control formula.

Detailed Description

Double-blind, randomized, controlled clinical trial. The purpose of this study is to evaluate the stool composition and GI tolerance of 140 healthy, term infants fed with an infant formula with a new fat blend plus L. reuteri vs a standard infant formula. All enrolled infants will participate in the trial for approximately 71 days.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Other
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
21 Days to 28 Days (Child)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Written Informed Consent
  • Infants whose parents/LAR have reached the legal age of majority in the Philippines
  • Infants whose parent(s)/LAR are willing and able to comply with scheduled visits, and the requirements of the study protocol
  • Infants whose parent(s)/LAR are able to be contacted directly by telephone throughout the study
  • Healthy term, singleton infant at birth
  • Between 21 to 28 days post-natal age at enrollment visit
  • Weight-for-age ≥ 5th and ≤ 95th percentile according to World Health Organization growth tables/charts
  • Infants of parent(s)/LAR who have previously made the decision to formula feed their infant at the time of enrollment

Exclusion Criteria

  • Infants with conditions requiring infant feedings other than those specified in the protocol
  • Infants receiving complementary foods or liquids
  • Infants who have a medical condition or history that could increase the risk associated with study participation or interfere with the interpretation of study results
  • Infants who are presently receiving or have received medications that could interfere with the interpretation of the study results

Outcomes

Primary Outcomes

Stool Consistency Score

Time Frame: Study Day 57, corresponding to infant age of 78-85 days

3-day Gastrointestinal (GI) Symptom and Behavior Diary, a parent-reported symptom diary to record stool consistency and stool frequency over the 3 consecutive days. A validated 5-point pictorial representation of the consistency of the stool for infants ≤1 year (1=watery, 2=runny, 3=mushy soft, 4=formed, 5=hard) will be provided in the stool diary for parent(s)/LAR to visually assess the infants' stools. Stool consistency will be compared between formula groups The baseline stool consistency value will also be included in the model as a covariate. the percentage of stools in each category (watery, runny, mushy soft, formed, or hard) will be calculated by visit for each infant and then will be summarized using the appropriate descriptive statistics. Figures composed of a series of histograms will be produced for each 3-day stool diary period.

Secondary Outcomes

  • Changes in Weight from baseline to 57 days(Study Day 57, corresponding to infant age of 78-85 days)
  • GI Tolerance(which corresponds to infant age of 21-28, 43-50, and 78-85 days.)
  • Changes in Length from baseline to 57 days(Study Day 57, corresponding to infant age of 78-85 days)
  • Changes in Head Circumference from baseline to 57 days(Study Day 57, corresponding to infant age of 78-85 days)

Investigators

Sponsor
Société des Produits Nestlé (SPN)
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials